MAPT and Alzheimer disease: Despite all the failed immunotherapy clinical trials in Alzheimer’s disease (AD), amyloid beta (Aß) and tau targeted immunotherapies are still at the forefront of therapeutic approaches (Hoskin et al., 2019; Cummings et al., 2019).